AngioDynamics (ANGO) has opened Q2 2026 earnings season with Q1 fiscal 2026 revenue of US$75.7 million and a basic EPS loss of US$0.26, as the market weighs those results against a current share price of US$11.44. Over recent quarters the company has reported revenue of US$67.5 million in Q1 2025, US$80.2 million in Q4 2025, and US$75.7 million in Q1 2026, while basic EPS losses moved from US$0.31 to US$0.15 and then to US$0.26. This keeps the focus on the company’s path back toward profitability. With trailing twelve month losses and modest revenue growth in the background, this latest report maintains attention on how quickly margins might tighten and whether analysts’ expectations on future earnings align with the reported numbers.

With the headline figures on the table, the next step is to see how these results compare with widely discussed narratives about AngioDynamics, highlighting where the data supports those views and where it may challenge them.

Losses steady around US$32.1 million over last 12 months

• On a trailing 12 month basis, AngioDynamics booked net income losses of US$32.1 million on US$300.7 million of revenue, which puts the net loss margin a little over 10% of sales.
• Analysts' consensus view expects profit margins to move from about an 11.6% loss today to a 3.1% profit in around three years. However, the recent quarterly net loss figures between US$4.4 million and US$12.8 million over the last five reported quarters show that the shift from loss to profit is still at an early stage.

Price to sales of 1.6x versus industry’s 3.1x

• The stock trades on a P/S of 1.6x compared with 3.1x for the broader US Medical Equipment industry and 9.1x for peers, so investors are paying less for each dollar of AngioDynamics revenue than for many competitors.
• Consensus narrative points to growing demand for minimally invasive therapies and new reimbursement support for products like NanoKnife as potential drivers for higher margin sales. However, the current 5% trailing revenue growth rate and ongoing losses over the past 12 months mean this lower P/S multiple still reflects a business that has not yet translated those growth drivers into profitability.

Stay close to how that 1.6x sales multiple and the US$11.44 share price respond as new data comes through, because the gap to peers could widen or close quickly once the profit story becomes clearer. See what the community is saying about AngioDynamics

EPS loss trends and 81.93% forecasted earnings growth

• Basic EPS over the last five reported quarters has stayed in loss territory, ranging between a loss of US$0.11 and US$0.33 per share, while the trailing 12 month EPS sits at a loss of US$0.78 per share.
• Bulls highlight forecasted earnings growth of 81.93% per year and an expected move to profitability within three years. However, the five year trend of losses increasing about 8.1% per year and the recent quarterly net losses of US$4.4 million to US$13.4 million show that the company still needs a clear shift in earnings power to match those optimistic expectations.
  • Supporters often point to operational savings initiatives that are expected to add about US$15 million a year by FY27, while the trailing 12 month loss of US$32.1 million illustrates how much of that benefit would first go toward simply closing the current earnings gap.
  • They also look at analyst expectations for earnings of about US$11.0 million and EPS of US$0.26 by around 2028, but with today’s US$0.78 loss per share, the turnaround implied in that path is large and will likely be judged one report at a time.

Bulls argue that these EPS losses are the set up for a sharp earnings swing if the margin story plays out as expected. 🐂 AngioDynamics Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AngioDynamics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See the numbers differently? Take a couple of minutes to test your own view against the data and turn it into a clear narrative with Do it your way

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding AngioDynamics.

See What Else Is Out There

AngioDynamics is still working through consistent EPS losses and net income of US$32.1 million in the red, which keeps profitability and earnings quality in question.

If you would prefer companies already delivering steadier progress on the bottom line, check out CTA_SCREENER_STABLE_GROWTH to focus on businesses with more consistent revenue and earnings momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.